Skip to main content
Top
Published in: Diabetologia 10/2012

Open Access 01-10-2012 | Commentary

Impact of transcription factor 7-like 2 (TCF7L2) on pancreatic islet function and morphology in mice and men

Author: E. Renström

Published in: Diabetologia | Issue 10/2012

Login to get access

Abstract

Common genetic variations in the gene encoding transcription factor 7-like 2 (TCF7L2) reveal the strongest association with type 2-diabetes known to date. These lead to impaired insulin production and output, but the mechanisms of disease remain incompletely known. In this issue of Diabetologia, two publications provide new insights into TCF7L2-dependent diabetes.
Literature
1.
go back to reference Grant SF, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedCrossRef Grant SF, Thorleifsson G, Reynisdottir I et al (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedCrossRef
2.
go back to reference Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336PubMedCrossRef Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336PubMedCrossRef
3.
go back to reference Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885PubMedCrossRef Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885PubMedCrossRef
4.
go back to reference Zeggini E, McCarthy MI (2007) TCF7L2: the biggest story in diabetes genetics since HLA? Diabetologia 50:1–4PubMedCrossRef Zeggini E, McCarthy MI (2007) TCF7L2: the biggest story in diabetes genetics since HLA? Diabetologia 50:1–4PubMedCrossRef
5.
go back to reference Zeggini E, Weedon MN, Lindgren CM et al (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336–1341PubMedCrossRef Zeggini E, Weedon MN, Lindgren CM et al (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336–1341PubMedCrossRef
6.
go back to reference Chang YC, Chang TJ, Jiang YD et al (2007) Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population. Diabetes 56:2631–2637PubMedCrossRef Chang YC, Chang TJ, Jiang YD et al (2007) Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population. Diabetes 56:2631–2637PubMedCrossRef
7.
go back to reference da Silva Xavier G, Mondragon A, Sun G, Chen L, McGinty JA, French PM, Rutter GA (2012) Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice. Diabetologia. doi:10.1007/s00125-012-2600-7 da Silva Xavier G, Mondragon A, Sun G, Chen L, McGinty JA, French PM, Rutter GA (2012) Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice. Diabetologia. doi:10.​1007/​s00125-012-2600-7
8.
go back to reference da Silva XG, Loder MK, McDonald A et al (2009) TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes 58:894–905CrossRef da Silva XG, Loder MK, McDonald A et al (2009) TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes 58:894–905CrossRef
9.
go back to reference Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K (2009) Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 18:2388–2399PubMedCrossRef Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K (2009) Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 18:2388–2399PubMedCrossRef
10.
go back to reference Zhou Y, Zhang E, Berggreen C et al (2012) Survival of pancreatic beta cells is partly controlled by a TCF7L2-p53-p53INP1-dependent pathway. Hum Mol Genet 21:196–207PubMedCrossRef Zhou Y, Zhang E, Berggreen C et al (2012) Survival of pancreatic beta cells is partly controlled by a TCF7L2-p53-p53INP1-dependent pathway. Hum Mol Genet 21:196–207PubMedCrossRef
11.
go back to reference Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163PubMedCrossRef Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163PubMedCrossRef
12.
go back to reference Prokunina-Olsson L, Welch C, Hansson O et al (2009) Tissue-specific alternative splicing of TCF7L2. Hum Mol Genet 18:3795–3804PubMedCrossRef Prokunina-Olsson L, Welch C, Hansson O et al (2009) Tissue-specific alternative splicing of TCF7L2. Hum Mol Genet 18:3795–3804PubMedCrossRef
13.
go back to reference Villareal DT, Robertson H, Bell GI et al (2010) TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 59:479–485PubMedCrossRef Villareal DT, Robertson H, Bell GI et al (2010) TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 59:479–485PubMedCrossRef
14.
go back to reference Liu Z, Habener JF (2008) Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 283:8723–8735PubMedCrossRef Liu Z, Habener JF (2008) Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 283:8723–8735PubMedCrossRef
15.
go back to reference Korinek V, Barker N, Moerer P et al (1998) Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 19:379–383PubMedCrossRef Korinek V, Barker N, Moerer P et al (1998) Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 19:379–383PubMedCrossRef
16.
go back to reference O Le Bacquer JK-C, S Gargani, N Delalleau, M Huyvaert, V Gmyr, P Froguel, B Neve, F Pattou (2012) TCF7L2 rs7903146 impairs islet function and morphology of non-diabetic individuals. Diabetologia. doi:10.1007/s00125-012-2660-8 O Le Bacquer JK-C, S Gargani, N Delalleau, M Huyvaert, V Gmyr, P Froguel, B Neve, F Pattou (2012) TCF7L2 rs7903146 impairs islet function and morphology of non-diabetic individuals. Diabetologia. doi:10.​1007/​s00125-012-2660-8
17.
go back to reference Le Bacquer O, Shu L, Marchand M et al (2012) TCF7L2 splice variants have distinct effects on beta-cell turnover and function. Hum Mol Genet 20:1906–1915CrossRef Le Bacquer O, Shu L, Marchand M et al (2012) TCF7L2 splice variants have distinct effects on beta-cell turnover and function. Hum Mol Genet 20:1906–1915CrossRef
18.
go back to reference Osmark P, Hansson O, Jonsson A, Ronn T, Groop L, Renstrom E (2009) Unique splicing pattern of the TCF7L2 gene in human pancreatic islets. Diabetologia 52:850–854PubMedCrossRef Osmark P, Hansson O, Jonsson A, Ronn T, Groop L, Renstrom E (2009) Unique splicing pattern of the TCF7L2 gene in human pancreatic islets. Diabetologia 52:850–854PubMedCrossRef
Metadata
Title
Impact of transcription factor 7-like 2 (TCF7L2) on pancreatic islet function and morphology in mice and men
Author
E. Renström
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2659-1

Other articles of this Issue 10/2012

Diabetologia 10/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.